Compugen: A Small Firm with Giant Technological Capabilities

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting

Compugen (CGEN) announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG for the treatment of advanced solid tumors, in an oral presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I on April 27, 2020 at 11:45 a.m. EST.

The presentation titled, “COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors”, will include updates from the dose-escalation arms of COM701 monotherapy and in combination with nivolumab.

Leave a Reply